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Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease characterized by articular and extra-articular
manifestations involving cardiovascular diseases (CVDs), which account for 30% to 50% of all deaths. In patients with
RA, atherosclerosis lesions occur earlier and have a more rapid evolution than in the general population. Beyond
mortality, the impact of CVD on quality of life, combined with the associated increase in health-care costs, renders
CVD in RA a major public health problem. Recent studies showed that patients with RA are characterized by the
presence of endothelial dysfunction (ED), which is recognized as a key event in the development of atherosclerosis.
By definition, ED is a functional and reversible alteration of endothelial cells, leading to a shift of the actions of the
endothelium toward reduced vasodilation, proinflammatory state and proliferative and prothrombotic properties. Al-
though the improvement of endothelial function is becoming an important element of the global management of
patients with RA, the mechanistic determinants of ED in RA are still poorly understood. Animal models of RA pro-
vide the unique opportunity to unravel the pathophysiological features of ED in RA. The present review summarizes
the available data on mechanisms underlying ED in animal models of RA and proposes attractive prospects in order
to discover novel therapeutic strategies of RA-associated ED.Introduction
Rheumatoid arthritis (RA) is a chronic systemic inflamma-
tory disease characterized by articular and extra-articular
manifestations, including cardiovascular diseases (CVDs),
which account for 30% to 50% of all deaths [1]. Recent
studies showed that atherosclerosis lesions occur earlier
and have a more rapid evolution in patients with RA than
in the general population [1]. Of interest, it is now
established that RA is equivalent to type 2 diabetes as
an independent risk factor for CVD [2,3]. Although
widely investigated, the underlying causes of the increased
prevalence of CVD among patients with RA remain to be
elucidated. Nonetheless, despite changes in the course of
the disease in recent years and new therapeutic options,
there is still no evidence that any particular intervention
can reduce CVD risk in RA [4]. Endothelial dysfunction
(ED) is thought to be a key event in the development of
atherosclerosis [5]. ED was first identified in patients with
RA by Bergholm and colleagues in 2002 [6] and is now* Correspondence: cdemouge@univ-fcomte.fr
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(CV) risk in RA [7]. However, the precise pathophysio-
logical mechanisms of ED in RA are still ill defined while
their identification is a prerequisite for the discovery of
drugs aiming to reduce CV risk in patients with RA. Be-
cause it is difficult to investigate these mechanisms in
humans, studies on animal models of RA are useful for
surrogate studies. The present review aimed to synthesize
available data on ED and its potential mechanisms in ani-
mal models of RA.
Animal models of arthritis used to study
endothelial dysfunction
Most of the studies were performed in the rat model of
adjuvant-induced arthritis (AIA) initially described by
Pearson [8]. This model is induced by a single injection
of a suspension containing heat-killed Mycobacterium
emulsified in oil into the tail base or the hind-paw
footpad. It is characterized by reliable, rapid onset and
progression and easily measurable polyarticular inflam-
mation, marked bone resorption, and periosteal bone
proliferation [9]. Clinical signs of polyarthritis usually
appear about 10 to 12 days after injection. The AIA
model is T cell- and neutrophil-dependent andl Ltd. The licensee has exclusive rights to distribute this article, in any medium,
is time, the article is available under the terms of the Creative Commons
rg/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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conducted in the mouse model of collagen-induced
arthritis (mCIA). In this model, genetically susceptible
strains of mice are immunized with injection in the tail
of heterologous type II collagen in complete Freund ad-
juvant, followed by a boost of collagen 3 weeks later [9].
Animals develop an autoimmune polyarthritis charac-
terized by cartilage destruction, bone resorption, syno-
vitis, and periosteal proliferation. Clinical signs of
polyarthritis appear about 10 to 12 days after boosting
[9]. The mCIA model involves T and B cells and is
complement-dependent [9]. In the two models, the se-
verity of arthritis is routinely assessed by determining
the thickness of each limb and/or a clinical score or
both, taking into account swelling and erythema of the
four limbs. The clinical scores can be further divided in
four grades from 0 (least severe) to 3 (most severe) [10].
Endothelial dysfunction in animal models of
arthritis
Definition of endothelial dysfunction
The endothelium, once considered a mere selectively
permeable barrier between bloodstream and vascular
wall, is now recognized as a crucial homeostatic organ,
fundamental for the regulation of the vascular tone and
structure [11]. It senses mechanical stimuli, such as
pressure and shear stress, and chemical stimuli, such as
hormones and locally secreted vasoactive substances. In
response to these stimuli, the endothelium releases
factors that regulate vasomotor function, inflammatory
processes, cell growth, and hemostasis (Figure 1).
Among the vasodilator substances produced by the
endothelium are nitric oxide (NO), prostacyclin (PGI2),
and endothelium-derived hyperpolarizing factors (EDHFs).










Figure 1 Endothelium-derived factors and normal endothelial functio
factor; ET-1, endothelin 1; NO, nitric oxide; PGI2, prostacyclin; TXA2, thrombo(ANG-II), and thromboxane A2 (TXA2) [11]. ‘Endothelial
dysfunction’ is a widely used term to describe any form of
abnormal functional and reversible alteration of endothe-
lial cells, leading to a shift of the actions of the endothe-
lium toward reduced vasodilation, proinflammatory state,
and proliferative and prothrombotic properties [12]. ED is
an important early event in the pathogenesis of athero-
sclerosis, contributing to plaque initiation and progression
[5]. In ‘traditional’ CVD, ED severity has a prognostic
value for CV events and the correction of ED may be as-
sociated with reduced CV risk [13].
Evidence of endothelial dysfunction in animal models of
arthritis
Endothelial function was studied in the widely used
model of isolated aortic rings that investigated the
effects of constrictive or relaxant drugs in isometric condi-
tions. The studies were conducted mainly on the AIA
model, and the assessment of ED was made at a time at
which inflammatory symptoms are maximal (that is, be-
tween day 24 and 35 after the injection of Mycobacterium
suspension, approximately 14 to 21 days after the onset of
arthritis). All studies unequivocally demonstrated a reduced
acetylcholine (ACh)-induced endothelium-dependent
vasorelaxation compared with control rats and therefore
attested to the presence of ED at this stage of the
disease (Table 1) [14-23]. It is noteworthy that the ED
severity mirrors the arthritis severity. Indeed, at day 24
post-injection in AIA, no alteration of ACh-induced
relaxation was found in grade 1 arthritic rats whereas
rats with grade 2 or 3 arthritis exhibited a reduced
relaxation to ACh [16]. Likewise, at day 35 post-injection,
we identified an inverse correlation between the maximal
effect of ACh and the arthritis grade [22]. Only two stud-
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Fang et al. [14] (1991) Male Wistar rat AIA M. butyricum (tail) Day 26 ↓ = PE = KCl =
Cinar et al. [15] (1998) Male rat (strain NR) AIA M. tuberculosis (pad) Day 26 ↓ = PE ↑ KCl =
Ulker et al. [16] (2000) Male Wistar rat AIA M. tuberculosis (pad) Day 29 ↓ in grade 2 and
3 = in grade 1
↓ in grade 2 and
3 = in grade 1
PE ↑ in grade 2,
PE ↓ in grade 3,
KCl ↑ in grade 2,
KCl = in grade 1 and 3
Can et al. [17] (2002) Male Wistar rat AIA M. tuberculosis (pad) Day 26 ↓ = NR
Haruna et al. [18] (2006) Male Lewis rat AIA M. butyricum (tail) Day 35 ↓ = NR
Haruna et al. [19] (2007) Male Lewis rat AIA M. butyricum (tail) Day 35 ↓ = NR
Nozaki et al. [20] (2007) Male Lewis rat AIA M. butyricum (tail) Day 24 ↓ = NR
Sakuta et al. [21] (2010) Male Lewis rat AIA M. butyricum (tail) Day 35 ↓ = NR
Prati et al. [22] (2011) Male Lewis rat AIA M. butyricum (tail) Day 35 ↓ = KCl =
Prati et al. [23] (2012) Male Lewis rat AIA M. butyricum (tail) Day 35 ↓ = NE, ANG-II, ET-1=
Reynolds et al. [24] (2012) Male DBA/1 mice CIA Chick collagen (NR) Day 24-27 = = Serotonin ↓, KCl ↓
He et al. [25] (2013) Male DBA/1 mice CIA Bovine collagen (tail) Day 56 ↓ = NR
Vascular reactivity was studied in the model of isolated aortic rings. ↑, increased; ↓, decreased; =, unchanged; ACh, acetylcholine; AIA, adjuvant-induced arthritis;
ANG-II, angiotensin II; CIA, collagen-induced arthritis; ET-1, endothelin-1; KCl, high potassium chloride; NE, norepinephrine; NR, not reported; PE, phenylephrine;
SNP, sodium nitroprusside.
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disease, ED was not observed [24] whereas in another
study, aortic ED was identified 8 weeks after collagen
injection [25].
Mechanisms of arthritis-induced endothelial
dysfunction
Decreased nitric oxide availability
In large vessels such as the aorta, NO released by endo-
thelial cells is a major contributor of vasorelaxation. The
presence of ED in AIA rats suggests that the vascular
bioavailability of NO is blunted (Figure 2). Production of
NO by vessels can involve both endothelial NO synthase
(eNOS) and inducible NOS (iNOS). The lack of effect of
the selective iNOS inhibitor 1400 W on the ACh-
induced vasodilation in AIA rats argues against a role of
iNOS in AIA-associated ED [23]. Thus, decreased NO
availability may result from different mechanisms, in-
cluding decreased eNOS protein expression, decreased
eNOS activity, decreased NO synthesis secondary to de-
creased availability of the NOS co-factor tetrahydro-
biopterin (BH4), deficiency in intracellular L-arginine
(the substrate of NOS), accumulation of the endogenous
eNOS inhibitor asymmetric dimethylarginine, or inacti-
vation of NO through excessive generation of super-
oxide anion (O2
–) [26].
Endothelial nitric oxide synthase expression/activity
In aortas from AIA rats, eNOS expression was found to
be unchanged [22] or increased [18,19] on day 35 post-injection. However, because eNOS is highly regulated at
the post-transcriptional level, eNOS expression is not a
good predictor of its activity [27,28]. It is therefore more
interesting to measure the ratio between the serine
1177-phosphorylated form of eNOS (P-eNOS), a marker
of the activated form of eNOS, and eNOS expression.
With this method, He and colleagues [25] demonstrated
that despite unchanged eNOS expression, the P-eNOS/
eNOS ratio was decreased in aortas from mCIA. Some-
what surprisingly, studies that performed the direct
measurement of NOS activity or NO production in aor-
tas from AIA rats are lacking. Recently, by using the
non-selective competitive NOS inhibitor, L-NG-nitroar-
ginine methyl ester (L-NAME), one study provided an
indirect argument for a blunted NOS activity in aortas
from AIA rats [23]. Alternatively, plasma levels of oxida-
tive degradation products of NO, including nitrite and
nitrate (NOx), have been proposed as surrogate markers
of vascular NOS activity [29]. However, plasma (nitrite +
nitrate) levels were found to be increased (approximately
two- to three-fold) at day 22 [30] and day 24 post-
injection in AIA rats [20] despite a reduced response to
ACh, thus questioning the measurement of plasma NOx
levels as a reliable tool to assess ED in arthritis.Uncoupling of endothelial nitric oxide synthase protein and
oxidative stress
Under certain conditions, NOS loses its ability to con-
vert L-arginine to L-citrulline but removes an electron
from NADPH (reduced form of nicotinamide adenine
Figure 2 Schematic representation of the mechanisms involved in decreased nitric oxide (NO) production in endothelial cells from
arthritic rats. Endothelial nitric oxide synthase (eNOS) catalyses the conversion of L-arginine to NO. The upregulation of arginase pathway and
the deficit in the co-factor of eNOS tetrahydrobiopterin (BH4) cause uncoupling of eNOS to generate superoxide anions (O2
–) which subsequently
scavenge NO to generate peroxynitrite (ONOO−). Angiotensin-II (ANG-II) might amplify O2
– production by activating NADPH (reduced form of
nicotinamide adenine dinucleotide phosphate) oxidase after ANG-II type 1 (AT1) receptor activation. Up and down arrows indicate increases or
decreases in amount or activity (from [14-23]).
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gen to yield O2
– instead of NO [31]. This phenomenon is
called ‘NOS uncoupling’ and results both in increased O2
–
production and in decreased NO availability. Under these
conditions, NO can react with O2
– to form peroxynitrite
(ONOO−), which itself is detrimental to the cell and con-
tributes to nitrative stress [32]. As uncoupling of eNOS
has been linked to its monomerization after disruption of
eNOS dimers, the measurement by Western blotting of
the ratio eNOS dimers/eNOS monomers is used as an
index of uncoupling [33]. Consistent with eNOS uncoup-
ling in AIA, the aortic ratio of eNOS dimers/monomers
was found to be decreased on day 35 post-injection [18].
The most prominent cause of NOS uncoupling is the loss
of the critical NOS cofactor BH4 [34]. In the AIA model,
on day 35 post-injection, O2
– production was measured in
homogenates of aortas incubated with or without NOS
substrate and various inhibitors [18]. The spontaneous
aortic production of O2
– was enhanced in AIA rats com-
pared with controls. Consistent with a role of NOS un-
coupling, incubation with the NOS inhibitor L-NAME
reduced O2
– production. The incubation with BH4 also re-
duced O2
– production, suggesting a contribution of BH4
deficiency to NOS uncoupling. This hypothesis was con-
firmed by the twofold decrease in serum BH4 levels in
AIA rats compared with controls [18]. Moreover, treat-
ment of AIA with BH4 led to the recovery of normalendothelial function, albeit not modifying the severity of
arthritis [18]. The uncoupling of eNOS is not the only
possible source of vascular O2
–. NADP (H) oxidase has
been reported as one of the most important sources of ex-
cess O2
– production in the vasculature [35]. In AIA,
mRNA expression of the aortic NADP (H) oxidase sub-
units p22phox, gp21phox, and p47phox was increased
[19,21], as was the activity of the enzyme [21]. Taken to-
gether, these results suggest that both eNOS uncoupling
and NADP (H) oxidase overexpression are the predomin-
ant sources of O2
– production in aortas from AIA rats.
The role of excessive O2
– production in ED was confirmed
by our demonstration that incubation of aortic rings of
AIA rats with Tempol, a membrane-permeable superoxide
dismutase mimetic, or with apocynin, an NAPD (H) oxi-
dase inhibitor, significantly improved ACh-induced vaso-
relaxation [23]. Of note, ONOO− can also directly lead to
uncoupling of NOS. The vascular levels of nitrotyrosine, a
marker of ONOO− formation, are enhanced in aortas of
AIA rats [18]. However, whether ONOO− contributes to
ED was not evaluated.
Increased arginase pathway
Besides BH4 depletion and oxidative stress as causes
for eNOS uncoupling, depletion of the NOS substrate
L-arginine secondary to arginase upregulation is a cause
for NOS uncoupling and ED. Arginase (EC 3.5.3.1) is a
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to L-ornithine and urea [36]. Mammalian arginases exist
in two distinct isoforms (type I and type II) which have
specific subcellular localizations and tissue distribu-
tions. Notably, both arginase isoforms are expressed by
endothelial and vascular smooth muscle cells (VSMCs)
[37]. During the last decade, evidence emerged that in-
creased arginase expression/activity contributes to ED as-
sociated with various CVDs [37]. Increased aortic arginase
activity and increased expression of type II arginase were
reported at day 35 post-injection in AIA rats [22]. It is
noteworthy that both activity and expression were posi-
tively correlated with the intensity of arthritis but not with
plasma interleukin-6 levels, suggesting that mechanisms
other than systemic inflammation are involved in the
upregulation of vascular arginase pathway in AIA. Incuba-
tion of aortic rings with Nw-hydroxy-nor-L-arginine
(nor-NOHA), a selective competitive arginase inhibitor,
improved ACh-induced vasorelaxation [23]. These data
were confirmed in a study in which the treatment of
AIA rats with nor-NOHA for 21 days after the onset of
arthritis normalized the endothelial function despite the
lack of impact of arthritis severity. Consistent with the
contributing role of arginase overexpression in NOS
uncoupling, increased NOS activity and decreased O2
–
production were identified as mechanisms contributing
to the beneficial effect of arginase inhibitor on endothe-
lial function [23].The role of endothelium-derived hyperpolarizing factor
Despite the ongoing debate of the molecular identity
and signaling pathways, the contribution of EDHFs to
the endothelium-dependent relaxation is considered an
important feature of normal endothelium function [38].
EDHF has been demonstrated unequivocally in various
blood vessels from different species, including humans
[39]. The acronym ‘EDHF’ is applied to a factor which
induces vascular relaxation in the presence of cyclo-
oxygenase (COX) plus NOS inhibitors and which is
inhibited by charybdotoxin (an inhibitor of high/inter-
mediate conductance Ca2+-activated K+ channels) + apa-
min (an inhibitor of small conductance Ca2+-activated K+
channels). EDHF induces a potassium-mediated event as-
sociated with a reduction in intracellular K+ in VSMCs
[40]. The role of EDHF in endothelial maintenance has
been introduced as a back-up mechanism during NO
deficiency [38]. Recent data reported the impairment of
aortic EDHF production after ACh challenge in AIA
rats, suggesting that the EDHF-mediated compensatory
dilator system is lacking in RA [23]. Interestingly, the
treatment with an arginase inhibitor restored the EDHF
contribution to that of control rats, suggesting a cross-
talk between NO and EDHF pathways in arthritis [23].The role of prostanoids
In addition to NO and EDHFs, endothelium-derived
prostaglandins and TXA2 are critical regulators of vascu-
lar tone in both physiological and pathological condi-
tions [41]. Physiologically, vasorelaxant prostanoids such
as PGI2 and vasoconstrictive prostanoids such as TXA2
are synthesized by COXs. COX-1 is expressed constitu-
tively and is usually abundant in all animal and human
endothelial cells, whereas endothelial COX-2 is induced
mainly during inflammatory response [41]. In a model of
rabbits with both chronic AIA and atherosclerosis, in-
creased COX-2 expression was reported in the femoral
artery [42]. In AIA rats, incubation of aortic rings with
the preferential COX-2 inhibitor NS-398 improved
ACh-induced vasodilation, thereby indicating that COX-
2 overactivation contributes to ED [23]. Likewise, treat-
ment of AIA rats with the COX-2 inhibitor nabumetone
from day 15 to 29 post-immunization normalized the
vascular response to ACh [16]. By using the TX synthase
inhibitor furegrelate, we demonstrated a deleterious role of
TX synthase overactivation in endothelial function in AIA
[23]. Somewhat surprisingly, overactivation of PGI2 syn-
thase is also involved in AIA-associated ED. Indeed, the
PGI2 synthase inhibitor tranylcypromine improved ACh-
induced vasodilation in aortic rings from AIA rats [23].
These results confirmed the janus face of PGI2 and suggest
that, as already described in animal models of hyperten-
sion [43], PGI2 can induce vasoconstriction in AIA rats.
The role of the renin-angiotensin-aldosterone system
The renin-angiotensin-aldosterone system (RAAS) plays an
important role in the physiology and pathology of the CV
system. ANG-II regulates blood pressure and electrolyte
homeostasis and contributes to the inflammatory response
in the vascular wall [44]. ANG-II enhances O2
– production
by stimulation of NADP (H) oxidase, thereby causing ED.
In ‘traditional’ CVD, treatment with angiotensin-converting
enzyme (ACE) inhibitors or angiotensin receptor blockers
(ARBs) led to a reduction of CV events [44]. In AIA rats,
vascular mRNA expression of ANG-II type 1 receptors and
mRNA expression/activity of ACE were increased as com-
pared with controls [21]. In addition, the perfusion of AIA
rats with ANG-II for 21 days from the onset of arthritis
exacerbated these dysregulations of RAAS while arthritis
symptoms were not affected. Moreover, treatment of AIA
rats with ARBs led to the improvement of aortic endothelial
function along with a decrease in aortic O2
– production.
Collectively, these data suggest a contributing role of
ANG-II in AIA-induced ED [21].
Pharmacological approaches to treat endothelial
dysfunction in animal models of arthritis
As shown in Table 2, only a few studies investigated the
effects of drugs on AIA-associated ED. Treatment of
Table 2 Effects of treatments on vascular reactivity in animal model of arthritis
Authors (year) Animal strain Arthritis model
Arthritogenetic agent
(injection zone)
Treatment Vascular reactivity Arthritis severity
Cinar et al. [15]
(1998)
Male rat (strain NR) AIA
M. tuberculosis (pad)
Vitamin E 100 mg/kg per day (im)
from day 0 to day 26 post-injection
↓ ACh, ↑ PE ↓
Ulker et al. [16]
(2000)
Male Wistar rat AIA
M. tuberculosis (pad)
Nabumetone 120 and
240 mg/kg per day (po) from
day 14 to day 28 post-injection
Normalization of
responses
to Ach and SNP
= (120 mg/kg per day)
↓ (240 mg/kg per day)
Can et al. [17]
(2002)
Male Wistar rat AIA
M. tuberculosis (pad)
Vitamin E 100 mg/kg per day (im)
from day 0 to day 26 post-injection
↑ ACh ↓
Nozaki et al. [20]
(2007)
Male Lewis rat AIA
M. butyricum (tail)
Keishibukuryogan 1–1.2 g/kg
per day (po) from
day 0 to day 25 post-injection
↑ ACh =
Haruna et al. [18]
(2006)
Male Lewis rat AIA
M. butyricum (tail)
BH4 20 mg/kg (ip) from
day 21 to day 35 post-injection
↑ ACh = SNP =
Haruna et al. [19]
(2007)
Male Lewis rat AIA
M. butyricum (tail)
Fluvastatin 5 mg/kg per day (po)
from day 21 to day 35 post-injection
↑ ACh =
Sakuta et al. [21]
(2010)
Male Lewis rat AIA
M. butyricum (tail)
Losartan 3 mg/kg per day (po) and
Irbesartan 5 mg/kg per day (po)
from day 14 to day 35 post-injection
↑ ACh = SNP =
Prati et al. [23]
(2012)
Male Lewis rat AIA
M. butyricum (tail)
Nor-NOHA 40 mg/kg per day (ip)
from day 14 to day 35 post-injection
↑ ACh= SNP =NE,
ANG-II, ET-1
=
He et al. [25]
(2013)
Male DBA/1 mice CIA
Bovine collagen (tail)
Simvastatin 50 mg/kg per day (po)
from day 7 before injection
to day 56 post-injection
↑ ACh = SNP =
Vascular reactivity was studied in the model of isolated aortic rings. ↑, increased; ↓, decreased; =, unchanged; ACh, acetylcholine; AIA, adjuvant-induced arthritis;
ANG-II, angiotensin II; BH4, tetrahydrobiopterin; CIA, collagen-induced arthritis; ET-1, endothelin-1; im, intramuscular; ip, intraperitoneal; KCl, high potassium
chloride; NE, norepinephrine; nor-NOHA, Nw-hydroxy-nor-L-arginine; NR, not reported; PE, phenylephrine; po, per os; SNP, sodium nitroprusside.
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irbesartan [21], or arginase inhibitor [23] administered
after the onset of arthritis fully restored the endothelial
response to ACh without any influence on the course of
arthritis. Recently, the same finding was found after a
preventive treatment with simvastatin in mCIA [25].
Such dissociation between vascular and clinical effects of
these drugs is very interesting since it suggests that pa-
tients with RA, even resistant to anti-rheumatic medica-
tions with regard to articular symptoms, could benefit
from therapies specifically developed to target ED. Two
studies investigated the effects of vitamin E on AIA-
associated ED but led to controversial results [15,17].
Given the paramount importance of reducing CV risk in
RA, there is a need to determine the effect of anti-
rheumatic medications on ED. In patients with RA,
studies investigating the impact of disease-modifying
anti-rheumatic drugs (DMARDs) or biologic agents on
ED are scarce and led to conflicting results [7,45-47]. It
is somewhat surprising that studies evaluating the effect
of anti-rheumatic drugs on the ED in animal models of
arthritis are lacking. Such studies need to be performed.
Conclusions
The studies presented in the present review provide
compelling evidence that aortic ED is impaired duringthe severe inflammatory phase of the AIA model, in
agreement with the presence of a macrovascular ED in
patients with established RA [7]. The available data ob-
tained in animal models identified several mechanisms
of ED: decreased endothelial NO production, excessive
endothelial O2
– production, deficiency in the NOS cofac-
tor BH4, upregulation of arginase, upregulation of NADP
(H) oxidase, and overactivation of COX-2, TX synthase,
and PGI2 synthase, thereby identifying future potential
targets for new therapeutic options to treat ED in pa-
tients with arthritis. However, many points are still unre-
solved and would benefit from further studies on animal
models of RA. A first point concerns the time course of
ED with respect to the arthritis symptoms and diagnosis.
Is ED occurring early or even before the onset of the dis-
ease? Is it long-lasting and persistent even though the
inflammatory phase is resolved? A second point con-
cerns the presence or not of ED in the microvasculature.
Microvascular dysfunction plays an important role in
the development of target organ damage in the heart
and kidney as well as in the development of CV risk fac-
tors [48,49]. Whether microvascular dysfunction occurs
early in the course of RA is not known and whether
microvascular ED mirrors macrovascular ED, and as
such occurs at the same time in the disease process, re-
main to be determined. A third point concerns the link
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ED. Animal studies revealed that the improvement
of endothelial function occurs even though the severity of
arthritis is unchanged, suggesting that the reduction of in-
flammation is not a prerequisite for the improvement of
endothelial function. Moreover, the role of the different
actors of atherogenesis such as cellular adhesion mole-
cules, cytokines, chemokines, vascular endothelial growth
factor, autoantibodies, and different cells of the immune
response such as macrophages or dendritic cells [46] in
ED has to be studied in animals. Finally, animal models
may help to define the effect of immunosuppressive drugs
such as DMARDs, anti-tumor necrosis factor-alpha, or
glucocorticoids on ED and the mechanisms behind their
effects.
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